Biocon aims to become the world's leading insulin company, capitalising on larger pharmaceutical rivals' strategic shift towards newer, high-margin GLP-1 diabetes therapies. The company plans to expand its insulin presence across 80 markets, focusing on value maximisation and addressing the indispensable need for insulin, particularly for Type-1 and late-stage Type-2 diabetics.
'The unregulated marketing has to stop. People are getting recommendations for this from gym trainers, from marriage counsellors -- that is simply unacceptable.' ''There are many ways to lose weight -- eat less, fast, exercise, eat healthy. That is how you lose weight.'
'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'
Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.
Novak Djokovic suggested that Serena Williams could see Wimbledon as the ideal venue to return to tennis.
While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
Of the donations, 48% is in kind -- such as food, clothing, or other household goods -- followed by cash (44%) and volunteering (30%) with non-profits, religious institutions, or community groups.
Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.
For patients, the immediate impact is a reduction in the final cost of therapies that often run into lakhs per month.
'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
Stars are taking the talon fashion to a whole new level!
The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.
Emcure Pharmaceuticals on Monday said it saw Poviztra, its newly launched semaglutide brand, as a "long-term" opportunity in India's fast-evolving obesity and cardiometabolic therapy market, even as price competition in the glucagon-like peptide-1 (GLP-1) segment intensified.
The bumper rise is due to the rising demand for the drug and patients' gradual shift towards its higher dosage.
The 23-time Grand Slam champion, who retired from professional tennis in 2022, will headline a multi-year national marketing campaign for GLP-1 drugs, a company spokesperson said.
'Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five times what it was five years ago.'
'Even though I'm just 31, I feel like I've seen a lot in my life, some voluntarily, some involuntarily.'
Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.
Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.
The $1.2 billion in-space manufacturing market is expected to grow and be worth more than $20 billion by 2033.
Priyanka Chopra had a 'much-needed super fun' outing when she attended a Diljit Dosanjh concert in Los Angeles.
'I thought helmets would help. So, I took a motorcycle helmet with a polycarbonate visor to WSC.'
Don't shy away from the bold graphic eyeliner!
The 32 year old Indo-Canadian YouTube star wore a mask to express her solidarity for the farmers in India.
Former Kerala minister M A Baby was elected as the CPI(M) general secretary at the 24th party congress in Madurai. Baby, who was a member of the Rajya Sabha from 1986 to 1998, has been a member of the Politburo since 2012. He succeeds Sitaram Yechury, who passed away last year.
In an Instagram post, the Instagram sensation revealed that she is bisexual.
The US-based drug maker Eli Lilly and Company will form strategic drug manufacturing and development alliances with major Indian pharmaceutical companies to tap the opportunities in contract research and manufacturing.
The Indian-origin Canadian YouTube star joins the long list of celebs using their fame to promote a good cause.
Young Indian boxer Krisha Verma won the gold in the women's 75kg category while five other signed off with silver medals at the inaugural U-19 World Championships organised by World Boxing in Colorado, USA.
YouTube sensation Lilly Singh gets you in the mood for winter with her latest cover for Vogue.
US-based pharma giants Eli Lilly and company has filed a case against two Indian drug makers, Aurobindo Pharma and Lupin alleging infringement of patent of its anti-depressant drug Cymbalta.
Eli Lilly and Company, the US-based multinational pharmaceutical major, has sued Sun Pharmaceuticals in the US, alleging the company infringed its patent on Gemzar, a blockbuster cancer drug.
Pharma major Nicholas Piramal India Ltd will develop and commercialise a select group of US-based Eli Lilly and Company's pre-clinical drug products that span multiple therapeutic areas.
Global pharmaceutical major Eli Lilly is exploring the possibility of introducing more products from its global portfolio in India.
India's largest IT services firm Tata Consultancy Services on Wednesday said it won a contract from Eli Lilly to provide various drug development services to the US pharma firm.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances